

Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

Activity Description and Educational Objectives

Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterized by reduced and/or defective production of red blood cells, platelets, and mature granulocytes, often resulting in anemia, bleeding, and increased risk of infection. Historically, there have been limited therapeutic options for MDS treatment, including blood cell transfusions, erythropoiesis-stimulating agents, and treatment of infections. Subsequently, DNA methyltransferase inhibitors and immunomodulators have shown survival benefits in MDS, leading to additional research on the efficacy of currently approved novel erythroid maturation agents in the setting of MDS-related anemia. Additionally, novel combinations and emerging therapies including cytidine deaminase inhibitors, anti-CD47 antibodies, NEDD8-activating enzyme inhibitors, telomerase inhibitors, and anti-TIM-3 antibodies are providing additional options.

In this CME/MOC/NCPD/ILNA-certified activity, an oncology nurse expert will discuss how to maximize clinical outcomes in lower- and higher-risk patients with MDS, with a focus on the current and emerging treatment landscapes, as well as expert insights and case discussions on individualized care and shared decision-making. The expert will review key safety and efficacy evidence for the treatment of MDS, highlighting practical applications for the MDS care team.

Upon completion of this accredited CE activity, participants should be better able to:

- Review clinical presentation, diagnostic-prognostic workups, risk stratification, and identification of transfusion needs of patients with MDS
- Interpret recent clinical evidence on currently approved and innovative emerging treatment strategies for managing low-risk as well as high-risk patients with MDS
- Develop educational strategies for patients with MDS related to therapeutic expectations, adherence, safety considerations, and differences among novel agent classes
- Employ strategies to manage treatment-related adverse events to enhance quality of life for patients with MDS

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the management of MDS.

Method of Participation

There are no fees for participating in or receiving credit for this accredited CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

Providership, Credit, and Support Physician Continuing Medical Education

Medical Learning Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and 1.0 Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

Medical Learning Institute, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:

1.0 point: Basic Concepts for Transplantation, Care Continuum, Diagnosis and Staging, Disease-Related Biology, Oncologic Emergencies, Oncology Nursing Practice, Preparative Regimens, Psychosocial, Quality of Life, Scientific Basis for Practice, Symptom Management, Treatment


The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.





This CME/MOC/NCPD activity is provided by Medical Learning Institute, Inc.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.



Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

Disclosure and Conflict of Interest Policy

Medical Learning Institute, Inc., is committed to providing high quality accredited continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this accredited CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this accredited CE activity, regardless of the amount or their view of the relevance to the accredited education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the accredited CE activity.

Disclosures

Chair/Planner

Sara M. Tinsley, PhD, APRN, AOCN Nurse Practitioner, Malignant Hematology Moffitt Cancer Center Courtesy Instructor University of South Florida, College of Nursing Tampa, Florida

Sara M. Tinsley, PhD, APRN, AOCN, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Celgene Corporation and Incyte Corporation. Speakers Bureau participant with Astellas Pharma US, Inc.; Bristol Myers Squibb; Celgene Corporation; Incyte; Novartis Pharmaceuticals Corporation; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

onDemand Multimedia Activity

If you have not done so already, please visit our website at **PeerView.com/EQN**, where you'll be able to view the presentation in its entirety and download the activity Practice Aids.





This CME/MOC/NCPD activity is provided by Medical Learning Institute, Inc.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.